FDA Revokes EUAs of Four COVID-19 Monoclonal Antibodies
Infectious Disease > > COVID-19-- Mostly ended drugs are no longer efficient versus distributing SARS-CoV-2 stress
by Ian Ingram, Managing Editor, MedPage Today December 13, 2024
The FDA on Friday withdrawed the emergency situation usage permissions (EUAs) of 4 monoclonal antibodies for COVID-19.
The 4 drugs-- bebtelovimab, sotrovimab, casirivimab/imdevimab (REGN-COV2), and tixagevimab/cilgavimab (Evusheld)-- had actually been licensed for COVID-19 as treatments or as pre- or post-exposure prophylaxis for people at high threat of extreme results.
Casirivimab/imdevimab had actually notoriously been utilized ...